Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label attachment file name title
tabling member	label

Search

1667713

	registered interest
	date	07/11/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Novel Foods: Regulation
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, with reference to page 20 of his Department's food strategy white paper, published on June 2022, what his planned timetable is for when the Food Standards Agency will review the novel foods regulatory framework.
	tabling member constituency	Cambridge
	tabling member printed	Daniel Zeichner
	uin	238
	answer	answer is ministerial correction date of answer 16/11/2023 answer text <p>The Food Standards Agency (FSA) is committed to maintaining the United Kingdom’s high standards of food and feed safety whilst also working hard to support innovation across the food system. The FSA has a programme of continuous improvement and reform that has been in place since the launch of the Regulated Products Service in January 2021.</p><p> </p><p>In June, the FSA published a summary of the findings of the review of the Novel Foods Regulatory Framework. Following this review, the FSA has focused resource to look at potential future options for more fundamental reform of the food and feed regulatory system. This has included surveying stakeholders across all regulated product regimes to gain their views on potential reforms.</p><p> </p><p>The FSA is in the process of analysing this information to develop reform plans and will provide further detail on these, including timetables, at the public FSA Board meetings in the future.</p> answering member constituency South Northamptonshire answering member printed Andrea Leadsom question first answered 16/11/2023 12:23:41 answering member 4117 label Biography information for Andrea Leadsom
	tabling member	4382 label Biography information for Daniel Zeichner

1667714

	registered interest
	date	07/11/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Novel Foods: Regulation
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, with reference to his Department's food strategy white paper, published on June 2022, what steps the Food Standards Agency is taking to help food producers conduct (a) safe and (b) limited tastings of novel food products.
	tabling member constituency	Cambridge
	tabling member printed	Daniel Zeichner
	uin	239
	answer	answer is ministerial correction date of answer 16/11/2023 answer text <p>Under retained EU Regulation 2015/2283, a novel food is only deemed safe to be placed on the market in Great Britain after the Food Standards Agency (FSA) has processed an application for the authorisation of the novel food.</p><p> </p><p>For foods that are still in the research and development phase prior to authorisation guidance issued by the FSA Advisory Committee on Novel Foods and Processes in 2002 confirms that taste trials are permitted as long as they are not conducted for marketing or advertising purposes.</p> answering member constituency South Northamptonshire answering member printed Andrea Leadsom question first answered 16/11/2023 12:37:36 answering member 4117 label Biography information for Andrea Leadsom
	tabling member	4382 label Biography information for Daniel Zeichner

1667715

	registered interest
	date	07/11/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Novel Foods
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, with reference to the Answer of 12 December 2022 to Question 105459 on Food: Research, what progress the Food Standards Agency has made in developing dedicated guidance materials for alternative protein companies developing novel foods and processes; and when he plans to publish that guidance.
	tabling member constituency	Cambridge
	tabling member printed	Daniel Zeichner
	uin	240
	answer	answer is ministerial correction date of answer 16/11/2023 answer text <p>The Food Standards Agency (FSA) has prepared an information page for its website that will provide guidance to companies producing cell-cultivated products that wish to apply for regulatory approval. This will be published before the end of November 2023.</p><p> </p><p>This page will outline information about the FSA’s regulated product application service, the regulations that apply to these cell-cultivated products, and information about labelling implications. Alongside this, the FSA has been providing pre-application support to businesses on an individual basis due to the novelty and complexity of this technology. This one-to-one engagement with business and industry has helped to inform and tailor our online guidance which will be available shortly.</p><p> </p><p>The FSA is also considering producing additional regulatory guidance for alternative protein producers as part of its wider aim to support business innovation whilst ensuring that food is safe and what it says it is. In addition to this, a new UK Research and Innovation project was announced on 9 November 2023 that will work on new safety rules for the United States of America, Singapore, United Kingdom and the European Union with a focus on creating standards for cell-cultivated protein.</p> answering member constituency South Northamptonshire answering member printed Andrea Leadsom question first answered 16/11/2023 12:39:36 answering member 4117 label Biography information for Andrea Leadsom
	tabling member	4382 label Biography information for Daniel Zeichner

1092655

	registered interest
	date	21/03/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Pharmacy: Safety
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps his Department has taken to manage risks to safety in compounding facilities in (a) NHS organisations and (b) commercial aseptic pharmacies.
	tabling member constituency	Cambridge
	tabling member printed	Daniel Zeichner
	uin	235304
	answer	answer is ministerial correction date of answer 28/03/2019 answer text <p>Hospital pharmacy aseptic services can be provided under either:</p><p>- a specific exemption for pharmacists within medicine legislation (derived from section 10 of the Medicines Act 1968); or</p><p>- a specials manufacturing licence from the Medicines and Healthcare products Regulatory Agency (MHRA).</p><p> </p><p>Either approach requires services to meet the standards set by the MHRA within nationally recognised Good Manufacturing Practice. Licensed facilities are inspected by the MHRA and section 10 facilities are audited by regional quality assurance specialists under an Executive Letter, describing the arrangements for auditing unlicensed National Health Service aseptic units. The outcomes and risk ratings are reviewed through the NHS England Specialist Pharmacy Service.</p><p> </p><p>Commercial aseptic pharmacies must hold a specials manufacturing licence from the MHRA to supply compounded aseptic products to the NHS. The MHRA has its own inspection team who visit and review licensed facilities including both NHS and commercial. The MHRA has regulatory enforcement powers to close, restrict or require improvement in these licensed facilities.</p><p> </p><p>Capital spend to support individual pharmacy, aseptic or other NHS compounding services has historically been locally determined or has been part of wider whole hospital developments and, as such, there is no central repository of such spend.</p><p> </p><p>NHS Improvement has, through the initial work of reviewing NHS-provided aseptic services, identified a range of challenges linked to such services, including workforce. The next stage of this work will focus on workforce provision within the wider strategic review. This work does not include non-NHS organisations. Health Education England is undertaking a review that, linked with the NHS Improvement strategic service review, will identify the pharmacy technical services workforce issues across all grades and workforce groups.</p><p> </p><p>Aseptically compounded products are prepared from medicines that, in line with all medicines, are covered by the Department’s European Union exit planning process and products would all be included within the six-week additional stockpiling being managed through pharmaceutical suppliers.</p><p><strong> </strong></p><p><strong> </strong></p> answering member constituency Gosport answering member printed Caroline Dinenage grouped question UIN 235305 235306 235307 question first answered 28/03/2019 16:18:41 answering member 4008 label Biography information for Dame Caroline Dinenage
	tabling member	4382 label Biography information for Daniel Zeichner

1092656

	registered interest
	date	21/03/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Pharmacy: Capital Investment
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how much capital funding has been spent on (a) pharmacy services, (b) aseptic pharmacy services and (c) compounding pharmacy services in each of the last five years.
	tabling member constituency	Cambridge
	tabling member printed	Daniel Zeichner
	uin	235305
	answer	answer is ministerial correction date of answer 28/03/2019 answer text <p>Hospital pharmacy aseptic services can be provided under either:</p><p>- a specific exemption for pharmacists within medicine legislation (derived from section 10 of the Medicines Act 1968); or</p><p>- a specials manufacturing licence from the Medicines and Healthcare products Regulatory Agency (MHRA).</p><p> </p><p>Either approach requires services to meet the standards set by the MHRA within nationally recognised Good Manufacturing Practice. Licensed facilities are inspected by the MHRA and section 10 facilities are audited by regional quality assurance specialists under an Executive Letter, describing the arrangements for auditing unlicensed National Health Service aseptic units. The outcomes and risk ratings are reviewed through the NHS England Specialist Pharmacy Service.</p><p> </p><p>Commercial aseptic pharmacies must hold a specials manufacturing licence from the MHRA to supply compounded aseptic products to the NHS. The MHRA has its own inspection team who visit and review licensed facilities including both NHS and commercial. The MHRA has regulatory enforcement powers to close, restrict or require improvement in these licensed facilities.</p><p> </p><p>Capital spend to support individual pharmacy, aseptic or other NHS compounding services has historically been locally determined or has been part of wider whole hospital developments and, as such, there is no central repository of such spend.</p><p> </p><p>NHS Improvement has, through the initial work of reviewing NHS-provided aseptic services, identified a range of challenges linked to such services, including workforce. The next stage of this work will focus on workforce provision within the wider strategic review. This work does not include non-NHS organisations. Health Education England is undertaking a review that, linked with the NHS Improvement strategic service review, will identify the pharmacy technical services workforce issues across all grades and workforce groups.</p><p> </p><p>Aseptically compounded products are prepared from medicines that, in line with all medicines, are covered by the Department’s European Union exit planning process and products would all be included within the six-week additional stockpiling being managed through pharmaceutical suppliers.</p><p><strong> </strong></p><p><strong> </strong></p> answering member constituency Gosport answering member printed Caroline Dinenage grouped question UIN 235304 235306 235307 question first answered 28/03/2019 16:18:41 answering member 4008 label Biography information for Dame Caroline Dinenage
	tabling member	4382 label Biography information for Daniel Zeichner

1092657

	registered interest
	date	21/03/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Pharmacy: Staff
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment his Department has made of workforce pressures in compounding pharmacies operated by (a) NHS organisations and (b) non-NHS organisations; and whether the pharmacy workforce will be included in the forthcoming NHS workforce plan.
	tabling member constituency	Cambridge
	tabling member printed	Daniel Zeichner
	uin	235306
	answer	answer is ministerial correction date of answer 28/03/2019 answer text <p>Hospital pharmacy aseptic services can be provided under either:</p><p>- a specific exemption for pharmacists within medicine legislation (derived from section 10 of the Medicines Act 1968); or</p><p>- a specials manufacturing licence from the Medicines and Healthcare products Regulatory Agency (MHRA).</p><p> </p><p>Either approach requires services to meet the standards set by the MHRA within nationally recognised Good Manufacturing Practice. Licensed facilities are inspected by the MHRA and section 10 facilities are audited by regional quality assurance specialists under an Executive Letter, describing the arrangements for auditing unlicensed National Health Service aseptic units. The outcomes and risk ratings are reviewed through the NHS England Specialist Pharmacy Service.</p><p> </p><p>Commercial aseptic pharmacies must hold a specials manufacturing licence from the MHRA to supply compounded aseptic products to the NHS. The MHRA has its own inspection team who visit and review licensed facilities including both NHS and commercial. The MHRA has regulatory enforcement powers to close, restrict or require improvement in these licensed facilities.</p><p> </p><p>Capital spend to support individual pharmacy, aseptic or other NHS compounding services has historically been locally determined or has been part of wider whole hospital developments and, as such, there is no central repository of such spend.</p><p> </p><p>NHS Improvement has, through the initial work of reviewing NHS-provided aseptic services, identified a range of challenges linked to such services, including workforce. The next stage of this work will focus on workforce provision within the wider strategic review. This work does not include non-NHS organisations. Health Education England is undertaking a review that, linked with the NHS Improvement strategic service review, will identify the pharmacy technical services workforce issues across all grades and workforce groups.</p><p> </p><p>Aseptically compounded products are prepared from medicines that, in line with all medicines, are covered by the Department’s European Union exit planning process and products would all be included within the six-week additional stockpiling being managed through pharmaceutical suppliers.</p><p><strong> </strong></p><p><strong> </strong></p> answering member constituency Gosport answering member printed Caroline Dinenage grouped question UIN 235304 235305 235307 question first answered 28/03/2019 16:18:41 answering member 4008 label Biography information for Dame Caroline Dinenage
	tabling member	4382 label Biography information for Daniel Zeichner

1092658

	registered interest
	date	21/03/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Pharmacy
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the effect on aseptic compounding pharmacies operated by (a) NHS organisations and (b) non-NHS organisations of the UK leaving the EU without a deal.
	tabling member constituency	Cambridge
	tabling member printed	Daniel Zeichner
	uin	235307
	answer	answer is ministerial correction date of answer 28/03/2019 answer text <p>Hospital pharmacy aseptic services can be provided under either:</p><p>- a specific exemption for pharmacists within medicine legislation (derived from section 10 of the Medicines Act 1968); or</p><p>- a specials manufacturing licence from the Medicines and Healthcare products Regulatory Agency (MHRA).</p><p> </p><p>Either approach requires services to meet the standards set by the MHRA within nationally recognised Good Manufacturing Practice. Licensed facilities are inspected by the MHRA and section 10 facilities are audited by regional quality assurance specialists under an Executive Letter, describing the arrangements for auditing unlicensed National Health Service aseptic units. The outcomes and risk ratings are reviewed through the NHS England Specialist Pharmacy Service.</p><p> </p><p>Commercial aseptic pharmacies must hold a specials manufacturing licence from the MHRA to supply compounded aseptic products to the NHS. The MHRA has its own inspection team who visit and review licensed facilities including both NHS and commercial. The MHRA has regulatory enforcement powers to close, restrict or require improvement in these licensed facilities.</p><p> </p><p>Capital spend to support individual pharmacy, aseptic or other NHS compounding services has historically been locally determined or has been part of wider whole hospital developments and, as such, there is no central repository of such spend.</p><p> </p><p>NHS Improvement has, through the initial work of reviewing NHS-provided aseptic services, identified a range of challenges linked to such services, including workforce. The next stage of this work will focus on workforce provision within the wider strategic review. This work does not include non-NHS organisations. Health Education England is undertaking a review that, linked with the NHS Improvement strategic service review, will identify the pharmacy technical services workforce issues across all grades and workforce groups.</p><p> </p><p>Aseptically compounded products are prepared from medicines that, in line with all medicines, are covered by the Department’s European Union exit planning process and products would all be included within the six-week additional stockpiling being managed through pharmaceutical suppliers.</p><p><strong> </strong></p><p><strong> </strong></p> answering member constituency Gosport answering member printed Caroline Dinenage grouped question UIN 235304 235305 235306 question first answered 28/03/2019 16:18:41 answering member 4008 label Biography information for Dame Caroline Dinenage
	tabling member	4382 label Biography information for Daniel Zeichner

1140333

	registered interest
	date	18/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Breast Cancer: Screening
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 12 June 2019 to Question 260033, what annual assessment is planned for the activity undertaken through the Genomic Laboratory infrastructure; and whether that information will be made public.
	tabling member constituency	Cambridge
	tabling member printed	Daniel Zeichner
	uin	279074
	answer	answer is ministerial correction date of answer 25/07/2019 answer text <p>NHS England collects management information on all services that it commissions and is establishing standardised reporting for the Genomic Laboratory Hubs. Management information, including activity and quality data, will be reviewed as part of NHS assurance with the Genomic Laboratory Hubs.</p><p>NHS England intends to make aggregate level information available for broad clinical themes, however, this will only be possible once robust and consistent reporting has been established.</p><p> </p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 25/07/2019 14:38:59 answering member 4008 label Biography information for Dame Caroline Dinenage
	tabling member	4382 label Biography information for Daniel Zeichner

1145449

	registered interest
	date	24/09/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cancer: Research
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how much funding the Government allocated to cancer research in each financial year since 2009.
	tabling member constituency	Cambridge
	tabling member printed	Daniel Zeichner
	uin	290349
	answer	answer is ministerial correction date of answer 30/09/2019 answer text <p>The Department’s National Institute for Health Research (NIHR) does not allocate funding for specific disease areas. The level of research spend in a particular area, such as cancer, is driven by factors including scientific potential and the number and scale of successful funding applications.</p><p>The NIHR’s expenditure on cancer research constitutes the largest investment in a disease area, and expenditure since 2009 is set out in the attached table.</p><p> </p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 30/09/2019 16:41:14 answering member 4008 label Biography information for Dame Caroline Dinenage attachment 1 file name PQ290349 attachment.docx title PQ290349 table
	tabling member	4382 label Biography information for Daniel Zeichner

942655

	registered interest
	date	16/07/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, with reference to the Office for Life Sciences Competitiveness Indicators, published in May 2018, what assessment his Department has made of the fall in the uptake of NICE-approved medicines.
	tabling member constituency	Cambridge
	tabling member printed	Daniel Zeichner
	uin	164450
	answer	answer is ministerial correction date of answer 24/07/2018 answer text <p>The Competitiveness Indicators published by the Office for Life Sciences show that the relative uptake rates of National Institute for Health and Care Excellence (NICE)-approved medicines have remained broadly stable over the last five years, with an increase in the overall level of uptake in the first year after release being offset by a slight fall in the fourth and fifth years.</p><p> </p><p>There are a number of reasons why the levels of uptake may vary including changes in the reported basket of medicines, and country level differences in disease burden and clinical practice.</p><p> </p><p>In addition to the Competitiveness Indicators, NHS Digital publishes a report on the use of medicines by the National Health Service in England, known as the Innovation Scorecard. The latest publication from July 2018 shows that 71% of NICE-approved medicines had higher levels of uptake than in the previous 12 months.</p><p> </p><p>The Innovation scorecard is available at the following link:</p><p> </p><p><a href="https://digital.nhs.uk/data-and-information/publications/statistical/nice-technology-appraisals-in-the-nhs-in-england-innovation-scorecard/nice-technology-appraisals-in-the-nhs-in-england-innovation-scorecard-to-december-2017" target="_blank">https://digital.nhs.uk/data-and-information/publications/statistical/nice-technology-appraisals-in-the-nhs-in-england-innovation-scorecard/nice-technology-appraisals-in-the-nhs-in-england-innovation-scorecard-to-december-2017</a></p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 24/07/2018 10:44:23 answering member 4008 label Biography information for Dame Caroline Dinenage
	tabling member	4382 label Biography information for Daniel Zeichner